These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

261 related articles for article (PubMed ID: 33438718)

  • 1. Post-marketing surveillance study of trifluridine/tipiracil in patients with metastatic colorectal cancer.
    Yoshino T; Uetake H; Funato Y; Yamaguchi Y; Koyama T; Ozawa D; Tajiri M; Muro K
    Jpn J Clin Oncol; 2021 Apr; 51(5):700-706. PubMed ID: 33438718
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Real-World Adherence in Patients with Metastatic Colorectal Cancer Treated with Trifluridine plus Tipiracil or Regorafenib.
    Patel AK; Barghout V; Yenikomshian MA; Germain G; Jacques P; Laliberté F; Duh MS
    Oncologist; 2020 Jan; 25(1):e75-e84. PubMed ID: 31591140
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The safety and efficacy of trifluridine-tipiracil for metastatic colorectal cancer: A pharmacy perspective.
    Chan BM; Hochster HS; Lenz HJ
    Am J Health Syst Pharm; 2019 Feb; 76(6):339-348. PubMed ID: 31361848
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Italian results of the PRECONNECT study: safety and efficacy of trifluridine/tipiracil in metastatic colorectal cancer.
    Zaniboni A; Barone CA; Banzi MC; Bergamo F; Blasi L; Bordonaro R; Bartolomeo MD; Costanzo FD; Frassineti GL; Garufi C; Giuliani F; Latiano TP; Martinelli E; Personeni N; Racca P; Tamburini E; Tonini G; Besse MG; Spione M; Falcone A
    Future Oncol; 2021 Jun; 17(18):2315-2324. PubMed ID: 33663264
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Review of metastatic colorectal cancer treatment pathways and early clinical experience of trifluridine/tipiracil in the UK named patient programme.
    Iveson T; Carter AM; Shiu KK; Spooner C; Stevens D; Mullamitha S
    BMC Cancer; 2020 Feb; 20(1):91. PubMed ID: 32013902
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Efficacy and Safety of Trifluridine/Tipiracil Treatment for Elderly Patients With Metastatic Colorectal Cancer in a Real-world Setting.
    Shibutani M; En W; Okazaki Y; Kashiwagi S; Fukuoka T; Iseki Y; Hirakawa K; Ohira M
    Anticancer Res; 2021 Dec; 41(12):6211-6216. PubMed ID: 34848475
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Retrospective cohort study of trifluridine/tipiracil (TAS-102) plus bevacizumab versus trifluridine/tipiracil monotherapy for metastatic colorectal cancer.
    Kotani D; Kuboki Y; Horasawa S; Kaneko A; Nakamura Y; Kawazoe A; Bando H; Taniguchi H; Shitara K; Kojima T; Tsuji A; Yoshino T
    BMC Cancer; 2019 Dec; 19(1):1253. PubMed ID: 31881856
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical Outcomes Following Trifluridine/Tipiracil Treatment for Patients With Metastatic Colorectal Cancer Ineligible for Regorafenib Treatment.
    Niisato Y; Moriwaki T; Fukuoka S; Masuishi T; Takashima A; Kumekawa Y; Kajiwara T; Yamazaki K; Esaki T; Makiyama A; Denda T; Hatachi Y; Suto T; Sugimoto N; Shimada Y
    Anticancer Res; 2021 Apr; 41(4):2203-2207. PubMed ID: 33813435
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and activity of trifluridine/tipiracil and ramucirumab in previously treated advanced gastric cancer: an open-label, single-arm, phase 2 trial.
    Kawazoe A; Ando T; Hosaka H; Fujita J; Koeda K; Nishikawa K; Amagai K; Fujitani K; Ogata K; Watanabe K; Yamamoto Y; Shitara K
    Lancet Gastroenterol Hepatol; 2021 Mar; 6(3):209-217. PubMed ID: 33508242
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Trifluridine/tipiracil: A practical guide to its use in the management of refractory metastatic colorectal cancer in Australia.
    Price T; Burge M; Chantrill L; Gibbs P; Pavlakis N; Shapiro J; Sjoquist K
    Asia Pac J Clin Oncol; 2020 Apr; 16 Suppl 1():3-12. PubMed ID: 32348018
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety profile of trifluridine/tipiracil monotherapy in clinical practice: results of the German compassionate-use program for patients with metastatic colorectal cancer.
    Kasper S; Kisro J; Fuchs M; Müller C; Schulz-Abelius A; Karthaus M; Rafiyan MR; Stein A
    BMC Cancer; 2018 Nov; 18(1):1124. PubMed ID: 30445951
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The subgroups of the phase III RECOURSE trial of trifluridine/tipiracil (TAS-102) versus placebo with best supportive care in patients with metastatic colorectal cancer.
    Van Cutsem E; Mayer RJ; Laurent S; Winkler R; Grávalos C; Benavides M; Longo-Munoz F; Portales F; Ciardiello F; Siena S; Yamaguchi K; Muro K; Denda T; Tsuji Y; Makris L; Loehrer P; Lenz HJ; Ohtsu A;
    Eur J Cancer; 2018 Feb; 90():63-72. PubMed ID: 29274618
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prediction of survival in patients with advanced, refractory colorectal cancer in treatment with trifluridine/tipiracil: real-world vs clinical trial data.
    Fernández Montes A; Carmona-Bayonas A; Jimenez-Fonseca P; Vázquez Rivera F; Martinez Lago N; Covela Rúa M; Cousillas Castiñeiras A; Gonzalez Villarroel P; De la Cámara Gómez J; Méndez JCM; Carriles Fernández C; Sanchez Cánovas M; Garcia García T
    Sci Rep; 2021 Jul; 11(1):14321. PubMed ID: 34253805
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluating trifluridine + tipiracil hydrochloride in a fixed combination (TAS-102) for the treatment of colorectal cancer.
    Mulet N; Matos I; Noguerido A; Martini G; Élez ME; Argilés G; Tabernero J
    Expert Opin Pharmacother; 2018 Apr; 19(6):623-629. PubMed ID: 29537896
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adherence, Dosing, and Managing Toxicities With Trifluridine/Tipiracil (TAS-102).
    Lee JJ; Chu E
    Clin Colorectal Cancer; 2017 Jun; 16(2):85-92. PubMed ID: 28242161
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effective Sequential Combined Chemotherapy with Trifluridine/Tipiracil and Regorafenib in Human Colorectal Cancer Cells.
    Matsuoka K; Nakagawa F; Tanaka N; Okabe H; Matsuo K; Takechi T
    Int J Mol Sci; 2018 Sep; 19(10):. PubMed ID: 30257515
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety, efficacy and patient-reported outcomes with trifluridine/tipiracil in pretreated metastatic colorectal cancer: results of the PRECONNECT study.
    Bachet JB; Wyrwicz L; Price T; Cremolini C; Phelip JM; Portales F; Ozet A; Cicin I; Atlan D; Becquart M; Vidot L; Mounedji N; Van Cutsem E; Taieb J; Falcone A
    ESMO Open; 2020 Jun; 5(3):e000698. PubMed ID: 32487542
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of food on the pharmacokinetics of TAS-102 and its efficacy and safety in patients with advanced solid tumors.
    Yoshino T; Kojima T; Bando H; Yamazaki T; Naito Y; Mukai H; Fuse N; Goto K; Ito Y; Doi T; Ohtsu A
    Cancer Sci; 2016 May; 107(5):659-65. PubMed ID: 26918279
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of Regorafenib and Trifluridine/Tipiracil According to Extended RAS Evaluation in Advanced Metastatic Colorectal Cancer Patients: A Multicenter Retrospective Analysis.
    Basso M; Signorelli C; Calegari MA; Lucchetti J; Zurlo IV; Dell'Aquila E; Arrivi G; Zoratto F; Santamaria F; Saltarelli R; Trovato G; Caira G; Angotti L; Schirripa M; Anghelone A; Schietroma F; Chilelli MG; Salvatore L; Pozzo C; Tortora G
    Target Oncol; 2024 May; 19(3):371-382. PubMed ID: 38613732
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of trifluridine/tipiracil in third-line and beyond for the treatment of patients with metastatic colorectal cancer in routine clinical practice: patterns of use and prognostic nomogram.
    Fernandez Montes A; Vazquez Rivera F; Martinez Lago N; Covela Rúa M; Cousillas Castiñeiras A; Gonzalez Villarroel P; de la Cámara Gómez J; Méndez Méndez JC; Salgado Fernández M; Candamio Folgar S; Reboredo López M; Carmona Campos M; Gallardo Martín E; Jorge Fernández M; Pellón Augusto ML; París Bouzas L; García Gómez J
    Clin Transl Oncol; 2020 Mar; 22(3):351-359. PubMed ID: 31073972
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.